{
    "nctId": "NCT00040014",
    "briefTitle": "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women",
    "officialTitle": "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen.",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "To determine the pharmacodynamic equivalence at steady state of the IM formulation of exemestane with the oral formulation in terms of plasma estrone sulphate inhibitory effect in postmenopausal women with advanced breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* other diagnosed with breast cancer\n* estrogen receptor positivity\n* Postmenopausal status\n* advanced disease\n* progression to previous tamoxifen therapy\n\nExclusion Criteria:\n\n* more than 1 chemotherapy and / or more than 1 hormonotherapy for advanced disease\n* previous hormonotherapy other than Tamoxifen",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}